Abattis Bioceuticals Leadership

Kent McParland is a Board Member at Abattis Bioceuticals Corp. He has worked as Chief Financial Officer at Cryptobloc Technologies Corp, Board Member at Cryptobloc Technologies Corp, and CFO/COO at Abattis Bioceuticals Corp. Kent works or has worked at Grant Thornton International Ltd, MNP, and Deloitte.

Patrick Mitchell is a Chief Operating Officer at ABATTIS BIOCEUTICALS CORP.

Vancouver, BC - November 19, 2013 - Abattis Bioceuticals Corp. (the ''Company'' or ''Abattis'') (OTC PINK: ATTBF) (CNSX:FLU), announces the appointment of Rene David as its Chief Financial Officer and Chief Operating Officer. Mr. David has over 20 years of experience in real estate development, finance, and business strategy. He started his career at VanCity, Canada's largest Credit Union as a real estate developer and then went into investment banking in Western Canada. He later expanded his interests to include the resource, and food and water industries, assisting corporations who are dealing with the globalization of local sources. In his normal course of duties, Mr. David's responsibilities include internal financial controls and analysis, procurement and contracts management. His continuous review of operating and capital plans is geared towards improving the internal controls and financial best practices in order to deliver highest value product and strong company values. Mr. David holds a Bachelor's of Commerce Degree in Finance and Diploma in Urban Land Economics from the University of British Columbia. While there he was a member of the UBC Men's Jr. Varsity Volleyball Team [although golf is his current passion]. He is the founding member of BLU Gold and Crimson Opportunities and was recognized in Business in Vancouver's ''Top 40 Under 40'', a regional recognition of exemplary individuals in business. He also holds directorships in several other publicly traded companies including a Vancouver-based, mineral exploration company primarily focused on the discovery of viable molybdenum deposits. Mr. Mike Withrow, Chief Executive Officer on behalf of the Company, stated, ''We were very selective in our search for an operations person who also had skills in finance. With Rene joining the Abattis team we have better financial controls and increased knowledge in structured funding to ensure value in transactions as we move forward. I am pleased to have Rene join our team and welcome him to be a key part of the growth we have planned.'' When asked to comment on his new appointment Mr. David replied, ''I'm excited to join Abattis, Canada's first public company in the medical marihuana application process to become a licensed producer. I look forward to helping Abattis become a leader in this emerging industry in Canada. As the industry risk profile decreases through credibility and awareness of the true medicinal properties and health benefits of marihuana, we strive to offer a vehicle for the best quality product, customer experience as well as a conduit to investment in one of the fastest growing industries in North America.''

Dr. Sexton began her informal study of phytochemicals as an herbalist and midwife, and continued on to the formal study of medicinal plants by earning a degree in horticulture. Her diverse undergraduate research on quercetin content in onions, Echinacea spp. led to biomedical research on brain tumors. She eventually enrolled in Bastyr University where she earned her doctorate in naturopathic medicine. There she continued her interest in phytochemical analysis work. She completed two pre-doctoral fellowships in collaboration with the University of Washington, studying the endogenous cannabinoid system and proteins up-regulated in neuro-inflammation. She went on to an individual post-doctoral fellowship at UW in the Department of Pharmacology, where she completed a clinical study in patients with Multiple Sclerosis, measuring immune parameters and Cannabis use. Her 6-year immersion in cannabinoid pharmacology, experience across analytical platforms, and specialty in botanical medicines led her to apply the knowledge gained to the analysis of Cannabis and thus founded the first Cannabis analysis lab in Washington State : Phytalytics in May of 2011. She is technical advisor and editor on the American Herbal Pharmacopoeia Cannabis Monograph, adopted by the Washington State Liquor Control Board for regulatory guidance of quality control of Cannabis and related products. In this capacity, she was an advisor to the WSLCB on the implementation of laboratory standards for Washington State under Initiative 502. She has published original research and serves as a Cannabis educator to the community and as a medical consultant. She maintains memberships with the International Cannabinoid Research Society (ICRS), the International Association of Cannabinoid Medicine (IACM), where she has presented her research internationally, and the Society of Cannabis Clinicians. She is currently the Executive Medical Director at the Center for the Study of Cannabis and Social Policy in Seattle, WA and serves on the Board of Directors for the Cannabis Training Institute and Americans for Safe Access Foundation. She is a member of the MJBA Women’s Alliance.

Kent McParland is a Board Member at Abattis Bioceuticals Corp. He has worked as Chief Financial Officer at Cryptobloc Technologies Corp, Board Member at Cryptobloc Technologies Corp, and CFO/COO at Abattis Bioceuticals Corp. Kent works or has worked at Grant Thornton International Ltd, MNP, and Deloitte.

Patrick Mitchell is a Chief Operating Officer at ABATTIS BIOCEUTICALS CORP.

Vancouver, BC - November 19, 2013 - Abattis Bioceuticals Corp. (the ''Company'' or ''Abattis'') (OTC PINK: ATTBF) (CNSX:FLU), announces the appointment of Rene David as its Chief Financial Officer and Chief Operating Officer. Mr. David has over 20 years of experience in real estate development, finance, and business strategy. He started his career at VanCity, Canada's largest Credit Union as a real estate developer and then went into investment banking in Western Canada. He later expanded his interests to include the resource, and food and water industries, assisting corporations who are dealing with the globalization of local sources. In his normal course of duties, Mr. David's responsibilities include internal financial controls and analysis, procurement and contracts management. His continuous review of operating and capital plans is geared towards improving the internal controls and financial best practices in order to deliver highest value product and strong company values. Mr. David holds a Bachelor's of Commerce Degree in Finance and Diploma in Urban Land Economics from the University of British Columbia. While there he was a member of the UBC Men's Jr. Varsity Volleyball Team [although golf is his current passion]. He is the founding member of BLU Gold and Crimson Opportunities and was recognized in Business in Vancouver's ''Top 40 Under 40'', a regional recognition of exemplary individuals in business. He also holds directorships in several other publicly traded companies including a Vancouver-based, mineral exploration company primarily focused on the discovery of viable molybdenum deposits. Mr. Mike Withrow, Chief Executive Officer on behalf of the Company, stated, ''We were very selective in our search for an operations person who also had skills in finance. With Rene joining the Abattis team we have better financial controls and increased knowledge in structured funding to ensure value in transactions as we move forward. I am pleased to have Rene join our team and welcome him to be a key part of the growth we have planned.'' When asked to comment on his new appointment Mr. David replied, ''I'm excited to join Abattis, Canada's first public company in the medical marihuana application process to become a licensed producer. I look forward to helping Abattis become a leader in this emerging industry in Canada. As the industry risk profile decreases through credibility and awareness of the true medicinal properties and health benefits of marihuana, we strive to offer a vehicle for the best quality product, customer experience as well as a conduit to investment in one of the fastest growing industries in North America.''

Dr. Sexton began her informal study of phytochemicals as an herbalist and midwife, and continued on to the formal study of medicinal plants by earning a degree in horticulture. Her diverse undergraduate research on quercetin content in onions, Echinacea spp. led to biomedical research on brain tumors. She eventually enrolled in Bastyr University where she earned her doctorate in naturopathic medicine. There she continued her interest in phytochemical analysis work. She completed two pre-doctoral fellowships in collaboration with the University of Washington, studying the endogenous cannabinoid system and proteins up-regulated in neuro-inflammation. She went on to an individual post-doctoral fellowship at UW in the Department of Pharmacology, where she completed a clinical study in patients with Multiple Sclerosis, measuring immune parameters and Cannabis use. Her 6-year immersion in cannabinoid pharmacology, experience across analytical platforms, and specialty in botanical medicines led her to apply the knowledge gained to the analysis of Cannabis and thus founded the first Cannabis analysis lab in Washington State : Phytalytics in May of 2011. She is technical advisor and editor on the American Herbal Pharmacopoeia Cannabis Monograph, adopted by the Washington State Liquor Control Board for regulatory guidance of quality control of Cannabis and related products. In this capacity, she was an advisor to the WSLCB on the implementation of laboratory standards for Washington State under Initiative 502. She has published original research and serves as a Cannabis educator to the community and as a medical consultant. She maintains memberships with the International Cannabinoid Research Society (ICRS), the International Association of Cannabinoid Medicine (IACM), where she has presented her research internationally, and the Society of Cannabis Clinicians. She is currently the Executive Medical Director at the Center for the Study of Cannabis and Social Policy in Seattle, WA and serves on the Board of Directors for the Cannabis Training Institute and Americans for Safe Access Foundation. She is a member of the MJBA Women’s Alliance.